Canada Markets closed
  • S&P/TSX

    17,190.25
    -206.31 (-1.19%)
     
  • S&P 500

    3,621.63
    -16.72 (-0.46%)
     
  • DOW

    29,638.64
    -271.73 (-0.91%)
     
  • CAD/USD

    0.7705
    +0.0013 (+0.1703%)
     
  • CRUDE OIL

    45.24
    -0.10 (-0.22%)
     
  • BTC-CAD

    25,394.21
    -87.11 (-0.34%)
     
  • CMC Crypto 200

    384.01
    +19.41 (+5.32%)
     
  • GOLD FUTURES

    1,780.60
    -0.30 (-0.02%)
     
  • RUSSELL 2000

    1,819.82
    -35.45 (-1.91%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • NASDAQ futures

    12,355.25
    +78.25 (+0.64%)
     
  • VOLATILITY

    20.57
    -0.27 (-1.30%)
     
  • FTSE

    6,266.19
    -101.39 (-1.59%)
     
  • NIKKEI 225

    26,666.69
    +233.07 (+0.88%)
     
  • CAD/EUR

    0.6448
    +0.0005 (+0.08%)
     

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Simply Wall St
·4 min read

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So should MediciNova (NASDAQ:MNOV) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.

See our latest analysis for MediciNova

Does MediciNova Have A Long Cash Runway?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. MediciNova has such a small amount of debt that we'll set it aside, and focus on the US$60m in cash it held at June 2020. Importantly, its cash burn was US$9.4m over the trailing twelve months. That means it had a cash runway of about 6.4 years as of June 2020. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
debt-equity-history-analysis

How Is MediciNova's Cash Burn Changing Over Time?

Because MediciNova isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. With the cash burn rate up 17% in the last year, it seems that the company is ratcheting up investment in the business over time. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Easily Can MediciNova Raise Cash?

Given its cash burn trajectory, MediciNova shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Since it has a market capitalisation of US$244m, MediciNova's US$9.4m in cash burn equates to about 3.9% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

So, Should We Worry About MediciNova's Cash Burn?

As you can probably tell by now, we're not too worried about MediciNova's cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. An in-depth examination of risks revealed 2 warning signs for MediciNova that readers should think about before committing capital to this stock.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.